What is the official website of Novartis Argentina ?

The official website of Novartis Argentina is https://www.novartis.com/ar-es/.

What is Novartis Argentina's cybersecurity risk score?

Novartis Argentina has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Argentina experienced?

According to Rankiteo, Novartis Argentina currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Argentina been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Argentina has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Argentina have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Argentina is not certified under SOC 2 Type 1.

Does Novartis Argentina have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Argentina does not hold a SOC 2 Type 2 certification.

Does Novartis Argentina comply with GDPR ?

According to Rankiteo, Novartis Argentina is not listed as GDPR compliant.

Does Novartis Argentina have PCI DSS certification ?

According to Rankiteo, Novartis Argentina does not currently maintain PCI DSS compliance.

Does Novartis Argentina comply with HIPAA ?

According to Rankiteo, Novartis Argentina is not compliant with HIPAA regulations.

Does Novartis Argentina have ISO 27001 certification ?

According to Rankiteo,Novartis Argentina is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Argentina operate in ?

Novartis Argentina operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Argentina have ?

Novartis Argentina employs approximately 101 people worldwide.

Does Novartis Argentina own any subsidiaries ?

Novartis Argentina presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Argentina have ?

Novartis Argentina's official LinkedIn profile has approximately 16,983 followers.

What is the NAICS classification code for Novartis Argentina ?

Novartis Argentina is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Argentina have a Crunchbase profile ?

No, Novartis Argentina does not have a profile on Crunchbase.

Does Novartis Argentina have a LinkedIn profile ?

Yes, Novartis Argentina maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-argentina.

How many cybersecurity incidents has Novartis Argentina experienced ?

As of June 29, 2026, Rankiteo reports that Novartis Argentina has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Argentina have ?

Novartis Argentina has an estimated 5,696 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Argentina faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Argentina

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Argentina Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis está reimaginando la medicina para mejorar y prolongar la vida de las personas. Como empresa líder mundial en medicamentos, utilizamos ciencia innovadora y tecnologías digitales para crear tratamientos transformadores en áreas de gran necesidad médica. En nuestra búsqueda por encontrar nuevos medicamentos, constantemente nos ubicamos entre las principales empresas del mundo que invierten en investigación y desarrollo. Los productos de Novartis llegan a casi 800 millones de personas en todo el mundo y estamos encontrando formas innovadoras de ampliar el acceso a nuestros últimos tratamientos. Lea nuestras normas de comunidad en:

Novartis Argentina A.I CyberSecurity Scoring

Scoring History

Novartis Argentina

Novartis Argentina CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Argentina

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Argentina Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Argentina

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Argentina in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Argentina in 2026.

Incident Types Novartis Argentina vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Argentina in 2026.

Incident History - Novartis Argentina (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Argentina Subsidiaries

Novartis Argentina

Pharmaceutical Manufacturing

Website: https://www.novartis.com/ar-es/

Company Size: 101

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Novartis EuropePharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis RomâniaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - ReumatologiePharmaceutical Manufacturing

Novartis Nederland - NeurologiePharmaceutical Manufacturing

Novartis Nederland - OncologiePharmaceutical Manufacturing

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologiePharmaceutical Manufacturing

Novartis Nederland - Cardiovascular, Renal & MetabolismPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Loading…

Novartis Argentina Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Loading…

NEWS

Novartis Argentina CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-13512

SUMMARY

A vulnerability was identified in Databend up to 1.2.881 on HTTP. This affects the function ClientSessionManager::state_key of the file src/query/service/src/servers/http/v1/session/client_session_manager.rs of the component Tenant Handler. The manipulation leads to authorization bypass. It is possible to initiate the attack remotely. The exploit is publicly available and might be used. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-28

Updated

Date2026-06-28

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-13511

SUMMARY

A vulnerability was determined in VoltAgent up to 2.1.17. Affected by this issue is the function handleGetMemoryConversation of the file packages/server-core/src/handlers/memory.handlers.ts of the component Memory REST API. Executing a manipulation of the argument conversationId can lead to improper authorization. The attack may be performed from remote. This attack is characterized by high complexity. The exploitation is known to be difficult. The exploit has been publicly disclosed and may be utilized. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-28

Updated

Date2026-06-28

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:P/I:N/A:N

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-13510

SUMMARY

A vulnerability was found in SimStudioAI sim up to 0.6.92. Affected by this vulnerability is an unknown functionality in the library apps/sim/lib/core/security/deployment.ts of the component Password Protection Handler. Performing a manipulation results in use of weak hash. The attack is possible to be carried out remotely. The attack's complexity is rated as high. The exploitation appears to be difficult. The exploit has been made public and could be used. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-28

Updated

Date2026-06-28

RISK INFORMATION (Score: 3.7)

cvss2

Base Score: 2.6

Complexity: HIGH

AV:N/AC:H/Au:N/C:P/I:N/A:N

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.9

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-13509

SUMMARY

A vulnerability has been found in RAGapp up to 0.1.5. Affected is the function FileHandler.upload_file/FileHandler.remove_file of the file src/ragapp/backend/controllers/files.py of the component Knowledge File Handler. Such manipulation leads to path traversal. The attack can be executed remotely. The exploit has been disclosed to the public and may be used. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-28

Updated

Date2026-06-28

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-13508

SUMMARY

A flaw has been found in khoj-ai khoj up to 2.0.0-beta.28. This impacts an unknown function of the file src/khoj/routers/api_chat.py of the component Conversation Sharing Handler. This manipulation of the argument conversation.agent causes incorrect authorization. Remote exploitation of the attack is possible. The exploit has been published and may be used. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-28

Updated

Date2026-06-28

RISK INFORMATION (Score: 5.5)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.1

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…